Freenome

AI multi-cancer early detection company using cell-free biology and machine learning

AI BiotechnologyPaid

Freenome is a clinical-stage company developing AI-powered blood tests for early cancer detection using cell-free biology — analyzing cell-free DNA, proteins, and other biomarkers circulating in blood that are shed by tumors. Its multiomics AI platform integrates signals across multiple biomarker types to detect cancer at earlier, more treatable stages when it is most curable. Freenome's lead program targets colorectal cancer detection as an alternative to colonoscopy. The company partners with health systems and insurers to demonstrate clinical utility and works toward FDA approval for its non-invasive cancer screening tests that could transform cancer outcomes through earlier detection.

Key Features

• ✓Liquid biopsy
• ✓Multi-cancer detection
• ✓AI biomarker analysis
• ✓Cell-free DNA
• ✓Early screening